Beam Therapeutics Inc(BEAM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.86 | Insider Own | 7.81% | Shs Outstand | 103.3M | Perf Week | -1.65% |
| Market Cap | 2.46B | Forward P/E | - | EPS next Y | -8.4% | Insider Trans | -4.75% | Shs Float | 95.2M | Perf Month | -1.98% |
| Enterprise Value | 1.55B | PEG | - | EPS next Q | -1.15 | Inst Own | 97.67% | Short Float | 28.93% | Perf Quarter | -9.51% |
| Income | -0.09B | P/S | 15.75 | EPS this Y | -447.29% | Inst Trans | 0.85% | Short Ratio | 15.55 | Perf Half Y | -18.43% |
| Sales | 0.16B | P/B | 2.3 | EPS next 5Y | - | ROA | -6.15% | Short Interest | 27.55M | Perf YTD | -14.18% |
| Book/sh | 10.34 | P/C | 2.13 | EPS past 3/5Y | 41.92% 28.04% | ROE | -8.08% | 52W High | -37.82% ($38.26) | Perf Year | -14.91% |
| Cash/sh | 11.16 | P/FCF | - | Sales past 3/5Y | 31.88% 466.27% | ROIC | -6.57% | 52W Low | 17.6% ($20.23) | Perf 3Y | 21.44% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 81.95% | Gross Margin | 85.74% | Volatility(W/M) | 4.04% 4.91% | Perf 5Y | -74.83% |
| Dividend TTM | - | EV/Sales | 9.94 | Sales Y/Y TTM | 158.88% | Oper. Margin | -242.27% | ATR (14) | 1.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.57 | EPS Q/Q | -17.25% | Profit Margin | -54.75% | RSI (14) | 43.24 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.57 | Sales Q/Q | -94.21% | SMA20 | -3.21% ($24.58) | Beta | 2.25 | Target Price | $51.07 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/8/4 | SMA50 | -8.35% ($25.96) | Rel Volume | 0.79 | Prev Close | $24.05 |
| Employees | 511 | LT Debt/Eq | 0.22 | EPS/Sales Surpr. | -6.65% -97.01% | SMA200 | -15.78% ($28.25) | Avg Volume(3M) | 1.77M | Price | $23.79 |
| IPO | 2020/2/6 | Option/Short | Yes/Yes | Trades | 8580 | Volume | 1,401,592 | Change | -1.08% |
🧬 This clinical-stage biotech company develops gene-editing therapies. Leveraging base-editing technology, it develops treatments for genetic and blood disorders and has drawn attention for its clinical progress. It is a biotech firm specializing in gene-editing therapeutics.
Over the past 1 year, on the lower side
38% below its 1-year high.
Traded less than usual. That is 79% of its average volume.
BEAM has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -447.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,575. Peers typically go for $1,575.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -74.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
28.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #79 of 594 in the industry
Based on market cap of $2B.
ADMA#78 Adma Biologics Inc $2B PER 15.7 BEAM#79 Beam Therapeutics Inc $2B PER - 
MBX#80 MBX Biosciences Inc $2B PER - 
NAMS#81 NewAmsterdam Pharma Company NV $2B PER - 
CLDX#82 Celldex Therapeutics Inc $2B PER - 
FAQ
What kind of company is BEAM?
BEAM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BEAM?
The market cap of BEAM is approximately $2.5B, ranking 1,871 within its sector.
What is the 52-week high and low for BEAM?
BEAM has recorded a 52-week high of $38.26 and a low of $20.23.
